News · 12 April 2026
New GSK drug shrinks ovarian, womb cancer tumours
Unsplash / National Cancer Institute
Patients worldwide facing gynaecological cancers could see promising new treatment options soon. In an early-stage trial, GSK's Mocertatug Rezetecan, known as Mo-Rez, reduced or removed tumours for most participants. This included 62% of ovarian cancer patients whose chemotherapy failed, and 67% of those with endometrial cancer. GSK now plans late-stage trials.
Reported by The Guardian · How we write briefs